Friday, November 17, 2023
This conference has already taken place.
Description
Lung cancer is the leading cause of cancer death in the U.S. Staying up to date on the latest developments in the care and treatment of lung cancer patients is an area of great public health need. This conference is designed for all oncologic healthcare providers. It will provide updates on:
- new developments in the perioperative treatment of lung cancer
- the treatment of patients with metastatic disease with actionable mutations and those without
- novel radiotherapeutic approaches, and
- the surgical management of patients with lung cancer, especially following induction chemoimmunotherapy.
For pricing information, see pricing tab below.
Dates and Times
Start: 11/17/2023 7:00 AM
End: 11/17/2023 12:30 PM
Objectives
At the conclusion of this activity, learners will be able to:
1. Understand the rationale, role, and application of preoperative therapy for patients with potentially resectable lung cancer.
2. Understand the importance and clinical relevance of awaiting broad based biomarker testing prior to starting treatment for NSCLC.
3. Be up to date on novel therapies of uncommon thoracic malignancies including SCLC, Mesothelioma, and Thymic malignancies.
4. Be acquainted with novel radiotherapeutic techniques, specifically the potential use of Proton therapy, in lung cancer.
Agenda
7 a.m. Breakfast
8 a.m. Welcome and Overview
Gregory Otterson MD, Co-Director, Thoracic Oncology Professor, Division of Medical Oncology The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
Dwight Owen MD, MSc Associate Professor, Division of Medical Oncology OSUCCC – James
SESSION 1
8:05 a.m. Surgery in The Era of Immunotherapy
Peter Kneuertz MD Associate Professor, Division of Thoracic Surgery The Ohio State University Wexner Medical Center
8:25 a.m. Q&A
8:30 a.m. Proton Therapy in Lung Cancer
Jeremy Brownstein, MD Assistant Professor, Department of Radiation Oncology OSUCCC – James
8:50 a.m. Q&A
8:55 a.m. What's Next in Immunotherapy for NSCLC
Dwight Owen, MD, MSc Associate Professor, Division of Medical Oncology OSUCCC – James
9:15 a.m. Q&A
9:20 a.m. Break
SESSION 2
9:30 a.m. Cell Therapies in Lung Cancer
Kai He, MD, PhD Assistant Professor, Division of Medical Oncology OSUCCC – James
9:50 a.m. Q&A
9:55 a.m. Keynote Presentation: Immunotherapy in Early Stage NSCLC
Patrick Forde, MBBCh Co-Director, Division of Upper Aerodigestive Malignancies Director, Thoracic Oncology Clinical Research Program Associate Professor of Oncology Johns Hopkins Medicine
10:40 a.m. Q&A
10:50 a.m. Break
SESSION 3
11:00 a.m. Novel Bronchoscopic Techniques in NSCLC Diagnosis and Treatment
Nicholas Pastis, MD Professor, Division of Pulmonary, Allergy, Critical Care and Sleep The Ohio State University Wexner Medical Center
11:20 a.m. Q&A
11:25 a.m. The Role of Microbiome in Lung Cancer
Dan Spakowicz, PhD Assistant Professor IM Medical Oncology OSUCCC – James
11:45 a.m. Q&A
11:55 a.m. Evaluation Submission and Closing Remarks
12:00 p.m. Lunch and Adjourn
Pricing
| Tier | Price |
|---|---|
| This is a Free Event | $0.00 |
Speakers
Location
The Grand Event Center
820 Goodale Boulevard
Grandview Heights, OH 43130
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.